Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, they can also lead on the downside when the growth story is over, …
so that Sanofi may sell a small percentage of the Regeneron common stock it owns to fund a portion of the cemiplimab …
The Company has also agreed to grant a limited waiver of the "lock-up" in the Amended and Restated Investor Agreement between the companies, so that Sanofi may sell up to an aggregate of 1.4 million shares of Regeneron Common Stock, …
Regeneron Pharmaceuticals Inc. (REGN)said that a Phase 3 study evaluating suptavumab or REGN2222, an antibody to respiratory syncytial virus or RSV, did not meet its primary endpoint of preventing medically-attended RSV infections in …
RTTNews10mon
It was a relatively slow week given the Thanksgiving break. Key developments this week include Biogen’s BIIB deal with Alkermes ALKS and Regeneron’s REGN disappointing data on Eylea. Recap of the Week’s Most Important Stories …
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria. The company has solid fundamentals for a short-term investment strategy. Based on current …
Key highlights of the week include Regeneron announcing positive data on Praluent, Sarepta seeking rapid approval of second DMD drug, while Orexigen filing for bankruptcy. Recap of the Week’s Most Important Stories Regeneron/Sanofi …
With earnings season drawing to a close, focus is back on pipeline and regulatory updates. While Regeneron Pharmaceuticals REGN, which has several pipeline catalysts lined up for the second half of the year, reported data on …
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stock has been a huge winner in the past. A $10,000 investment in the biotech 10 years ago would be worth more than $200,000 today. Regeneron's shareholders have been on a roller …
Key highlights of the week include Regeneron announcing positive data on Praluent, Sarepta seeking rapid approval of second DMD drug, while Orexigen filing for bankruptcy. Recap of the Week’s Most Important Stories Regeneron/Sanofi …